Research programme: asthma therapy - GlaxoSmithKline/Ventaira

Drug Profile

Research programme: asthma therapy - GlaxoSmithKline/Ventaira

Alternative Names: Asthma therapy research programme - GlaxoSmithKline/Ventaira

Latest Information Update: 15 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Ventaira Pharmaceuticals
  • Developer Battelle; GlaxoSmithKline
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 29 Oct 2007 Ventaira Pharmaceuticals has been acquired and merged into Battelle
  • 08 Jan 2004 BattellePharma is now called Ventaira Pharmaceuticals
  • 29 Oct 2002 Preclinical trials in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top